newsfilter
← Latest News
GlobeNewswire·

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for